In vitro anti-lymphoma activity of the first-in-class pan-NOTCH transcription inhibitor CB-103

Br J Haematol. 2023 Mar;200(5):669-672. doi: 10.1111/bjh.18576. Epub 2022 Dec 9.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Lymphoma* / drug therapy
  • Lymphoma* / pathology
  • Receptors, Notch

Substances

  • Antineoplastic Agents
  • Receptors, Notch

Grants and funding